关注
Justin M Watts
Justin M Watts
Associate Professor of Medicine, University of Miami
在 miami.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Functional genomic landscape of acute myeloid leukaemia
JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ...
Nature 562 (7728), 526-531, 2018
11112018
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ...
Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020
3452020
In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in corticobasal degeneration
A Gerhard, J Watts, I Trender‐Gerhard, F Turkheimer, RB Banati, K Bhatia, ...
Movement disorders: official journal of the Movement Disorder Society 19 (10 …, 2004
1622004
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ...
Blood advances 4 (9), 1894-1905, 2020
1542020
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ...
Cancer cell 40 (8), 850-864. e9, 2022
1422022
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ...
Leukemia 35 (12), 3542-3550, 2021
1212021
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies
SE Kurtz, CA Eide, A Kaempf, V Khanna, SL Savage, A Rofelty, I English, ...
Proceedings of the National Academy of Sciences 114 (36), E7554-E7563, 2017
1042017
Acute promyelocytic leukemia: what is the new standard of care?
JM Watts, MS Tallman
Blood reviews 28 (5), 205-212, 2014
1042014
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
MA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ...
Leukemia 35 (7), 2119-2124, 2021
982021
Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia …
DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ...
Blood 134, 673, 2019
972019
Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial
N Gangat, C Marinaccio, R Swords, JM Watts, S Gurbuxani, A Rademaker, ...
Clinical cancer research 25 (16), 4898-4906, 2019
762019
Recent advances in the understanding and treatment of acute myeloid leukemia
J Watts, S Nimer
F1000Research 7, 2018
762018
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
A Hochhaus, C Gambacorti-Passerini, C Abboud, BT Gjertsen, ...
Leukemia 34 (8), 2125-2137, 2020
742020
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, SN Dinner, ...
The Lancet Haematology 10 (1), e46-e58, 2023
712023
Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies
G Falchook, S Rosen, P LoRusso, J Watts, S Gupta, CC Coombs, ...
Clinical Cancer Research 26 (6), 1247-1257, 2020
702020
CARM1 is essential for myeloid leukemogenesis but dispensable for normal hematopoiesis
SM Greenblatt, N Man, PJ Hamard, T Asai, D Karl, C Martinez, D Bilbao, ...
Cancer cell 33 (6), 1111-1127. e5, 2018
662018
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
RT Swords, PL Greenberg, AH Wei, S Durrant, AS Advani, MS Hertzberg, ...
Leukemia research 50, 123-131, 2016
662016
Advances in acute myeloid leukemia: recently approved therapies and drugs in development
M Stanchina, D Soong, B Zheng-Lin, JM Watts, J Taylor
Cancers 12 (11), 3225, 2020
652020
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
J Taylor, D Pavlick, A Yoshimi, C Marcelus, SS Chung, JF Hechtman, ...
The Journal of clinical investigation 128 (9), 3819-3825, 2018
642018
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
RT Swords, D Azzam, H Al-Ali, I Lohse, CH Volmar, JM Watts, A Perez, ...
Leukemia Research 64, 34-41, 2018
552018
系统目前无法执行此操作,请稍后再试。
文章 1–20